Clinical Snippets

        Stratum Corneum Ceramide Alterations Predict Exacerbation of Atopic Dermatitis

        Figure thumbnail fx1

        High-Density Lipoprotein and Triglyceride: Effective Predictor of Incident Psoriasis Risk

        Figure thumbnail fx2

        Acquired Melanocytic Neoplasms Commonly Cluster

        Figure thumbnail fx3

        Polygenic Architecture Contributes to Age of Onset of AD in Japanese Patients

        Although GWASs have uncovered loci implicated in allergic diseases, convincing evidence about genetic associations that impact the age of onset of AD is lacking. Hikino et al. utilized linear regression analysis to examine the age of onset of AD and 17 SNPs from recent GWAS using 1,344 patients with AD in a Japanese population. The risk allele rs59039403 in NLRP10 was significantly associated with earlier age of onset by 3.28 years, and each of the other significant loci accelerated the age of onset by an average of 0.46 years. This study suggests that early- and late-onset AD have different underlying genetic architectures. See page 3337

        Combination Treatment for Patients with Vitiligo

        Patients with vitiligo often improve after treatment with phototherapy and topical corticosteroids or calcineurin inhibitors. Furthermore, inhibition of Jak1/2 signaling, which drives IFN-γ‒mediated pathogenesis, with ruxolitinib cream has also been associated with considerable repigmentation in this patient population. In an open-label extension study of 19 patients who had received ruxolitinib cream alone in a phase 2 randomized trial, Pandya et al. found that treatment with ruxolitinib cream combined with narrow-band UVB phototherapy was well-tolerated and resulted in improvement in facial and total body repigmentation in 78.9 and 94.7% of patients, respectively. These effects were also observed in most patients who did not show significant improvement after 24 weeks of ruxolitinib cream alone. See page 3352